934664-19-4

Basic information

• Product Name: 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)benzoyl fluoride
• Synonyms: 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)benzoyl fluoride;Benzoyl fluoride, 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-;3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl fluoride
• CAS NO: 934664-19-4
• Molecular Formula: C₁₃H₆F₄INO
• Molecular Weight: 395.0909228
• Mol File: 934664-19-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)benzoyl fluoride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)benzoyl fluoride(934664-19-4)
• EPA Substance Registry System: 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)benzoyl fluoride(934664-19-4)

Safety Data

• Hazardous Substances Data: 934664-19-4(Hazardous Substances Data)

Usage

General Description

3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl fluoride is a chemical compound with the molecular formula C13H6F4IN2O2. It is a benzoyl fluoride derivative with two fluorine atoms and one iodine atom attached to a phenylamino group. 3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl fluoride is commonly used in pharmaceutical research as a building block for the synthesis of potential drug candidates due to its ability to act as a fluorine source and as a reactive intermediate in chemical reactions. It has also been studied for its potential application in positron emission tomography (PET) imaging as a tracer for detecting certain biological targets in the body. However, 3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl fluoride is highly reactive and should be handled with caution due to its potential for causing skin and eye irritation.

Upstream product

• 391211-97-5 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 

Downstream Products

• 934660-99-8 3-[(1R)-1-aminoethyl]-1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)azetidin-3-ol 
• 1373446-70-8 1,1-dimethylethyl {(1S)-1-[1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-hydroxyazetidin-3-yl]ethyl}carbamate 
• 934660-98-7 3-[(1S)-1-aminoethyl]-1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)azetidin-3-ol 
• 934665-56-2 tert-butyl (S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl]-3-hydroxy-3-azetidinyl}perhydropyridine-1-carboxylate 
• 934660-93-2 [14C]-GDC-0973 
• 934661-40-2 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-{[(1-methylethyl)amino]methyl}azetidin-3-ol 
• 934665-71-1 1,1-dimethylethyl {[1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-hydroxyazetidin-3-yl]methyl}ethylcarbamate 
• 934666-30-5 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-{4-[(2-nitrophenyl)sulfonyl]piperazin-2-yl}azetidin-3-ol 
• 934666-24-7 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-(6-methylpiperidin-2-yl)azetidin-3-ol acetate salt 
• 1035348-70-9 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-(morpholin-4-ylmethyl)azetidin-3-ol trifluoroacetate salt 
• 934665-82-4 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-(1H-imidazol-2-ylmethyl)azetidin-3-ol acetate salt 
• 934665-94-8 1,1-dimethylethyl {(1R)-1-[1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-hydroxyazetidin-3-yl]ethyl}carbamate 
• 934665-56-2 tert-butyl 2-(1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-hydroxyazetidin-3-yl)piperidine-1-carboxylate 

Relevant articles and documents

Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC-0973)

The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S) -piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials.

METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.